GeneOS
Clinical Platform
Meridian Wellness Center
SK
Dr. Sarah Kim
Clinical Overview
Meridian Wellness Center — Monday, June 30, 2026
Active Patients
24
Blueprints Ready
3
Protocols Active
7
Avg Outcome Score
91%
🔔 Today’s Action Items
3 urgent
Blueprint ready: Patient #A-0047
Inflammatory profile — clinical review pending
Exosome resample due: Patient #A-0031
Week 8 follow-up — 8 days past window
Protocol refinement complete: Patient #A-0019
MTHFR optimization adjusted — ready to deploy
📋 Recent Patient Activity
View all →
| Patient | Status | Last Analysis | Blueprint | Protocol | Action |
|---|---|---|---|---|---|
| A-0047 | Blueprint Ready | Today | ✓ Ready | Pending | |
| A-0039 | Protocol Active | 3 days ago | ✓ Done | Week 6/12 | |
| A-0031 | Resample Due | 8 days ago | ✓ Done | Active | |
| A-0028 | Intake Complete | 2 weeks ago | Processing | — | |
| A-0015 | Completed | 1 month ago | ✓ Done | ✓ Done |
⚗️ Lab Queue
View all →
GNS-2847ETA ~1h
Patient A-0047 · Allelic + Exosome
Allelic AnalysisComplete ✓
Exosome ProcessingProcessing
GNS-2831Complete
Patient A-0031 · Exosome
Exosome ProcessingDone ✓
GNS-2819ETA ~2h
Patient A-0028 · Allelic
Allelic AnalysisDone ✓
Blueprint GenerationGenerating
🦉
🦉 Hypatia Clinical Intelligence
Pattern flagged across 4 patients with IL6 variants and your current BPC-157 dosing. Recommend reviewing the batch protocol for inflammatory responders — titration adjustment may significantly improve week-4 outcomes.
Patient Management
24 active patients — anonymized by default
A-0047
Jun 3, 2026
Blueprint ReadyProtocol: PendingLast exosome: Today
A-0039
May 18, 2026
Protocol ActiveWeek 6/12Last exosome: 3d ago
A-0031
May 2, 2026
Resample DueProtocol: ActiveLast exosome: 8d ago
A-0028
Apr 24, 2026
Intake CompleteBlueprint: ProcessingLast exosome: 2w ago
A-0022
Apr 10, 2026
Protocol ActiveWeek 9/12Last exosome: 5d ago
A-0019
Mar 28, 2026
Protocol RefinedWeek 11/12Last exosome: 1d ago
A-0015
Feb 14, 2026
CompletedProtocol: DoneLast exosome: 1mo ago
Lab Queue
Sample submission and processing status
Upload Gene Data
Drag and drop or click to select
Accepts: 23andMe · AncestryDNA · VCF · Clinical VCF · FASTQ
Sample Submission
⚗️ Processing Queue
3 active| Sample ID | Patient | Type | Submitted | Status | ETA | Action |
|---|---|---|---|---|---|---|
| GNS-2847 | A-0047 | Allelic + Exosome | 2h ago | Allelic ✓Exosome ↻ | ~1h | |
| GNS-2831 | A-0031 | Exosome | 6h ago | Complete ✓ | Done | |
| GNS-2819 | A-0028 | Allelic | 1 day ago | Blueprint Generating | ~2h |
Genetic Blueprints
Structured, actionable patient profiles ready for clinical use
Pending Review
Reviewed
Archived
Patient A-0047
PENDING REVIEW
Priority Pathways
1
Methylation
MTHFR C677T heterozygous — estimated 35% enzyme reduction in folate metabolism
2
Inflammation
IL6 -174G>C elevated — environmental trigger likely, systemic inflammatory baseline elevated
3
Detoxification
CYP1B1 variant detected — estrogen metabolism and phase I detox pathway affected
Actionable Interventions
→Methylated folate (not folic acid) — MTHFR bypass priority. L-5-MTHF 400–800mcg daily.
→Anti-inflammatory peptide protocol — BPC-157 250mcg + TB-500 5mg recommended. Review batch IL6 protocol.
→Liver detox pathway support — DIM + sulforaphane, estrogen clearance via CYP1B1 optimization.
⚠ Contraindications Flagged
⚠ High-dose B6 — MTHFR interaction risk, peripheral neuropathy at >100mg
⚠ Estrogen-dominant compounds — CYP1B1 metabolic conflict, monitoring required
Recommended Protocol
IL6 Inflammatory Response — MTHFR Modified Stack · See Protocol Library →
Patient A-0039
PENDING REVIEW
Priority Pathways
1
Catecholamine Balance
COMT Val158Met — reduced dopamine/norepinephrine clearance, stress response dysregulation
2
Lipid Metabolism
APOE ε4 heterozygous — cardiovascular risk elevation, lipid clearance impairment
Patient A-0028
GENERATING
Blueprint generation in progress. Hypatia is analyzing 847 markers across 6 pathways.
72% complete · ~2h remaining
Protocol Management
Build and monitor bespoke peptide matrices and smart patch stacks
💊 Peptide Matrix — Patient A-0047
| Peptide | Dose | Frequency | Route | Molecular Target | Action |
|---|---|---|---|---|---|
BPC-157 Anti-inflammatory / Tissue Repair | 250 mcg | Daily × 12wk | SubQ | IL6 pathway | |
TB-500 Actin regulation / Repair signaling | 5 mg | 2× weekly | SubQ | TGF-β / IGF-1 | |
Epitalon Telomere / Pineal regulation | 10 mg | 10 days/cycle | SubQ | Epigenetic | |
GHK-Cu Copper peptide / Tissue regeneration | 2 mg | 3× weekly | Topical/SubQ | Repair signal |
🩹 Smart Patch Stack — Patient A-0047
TransdermalAnti-inflammatory matrix patch72h delivery · Rotate application sites
EpigeneticMethylation support patch24h delivery · Morning application
Active Protocols
| Patient | Protocol Week | Peptide Count | Last Adjustment | Next Review | Status | Action |
|---|---|---|---|---|---|---|
| A-0039 | Week 6/12 | 3 peptides | 2 days ago | Week 8 | On Track | |
| A-0031 | Week 7/12 | 4 peptides | 8 days ago | Resample Due | Review Needed | |
| A-0022 | Week 9/12 | 5 peptides | 5 days ago | Week 12 | Optimal | |
| A-0019 | Week 11/12 | 4 peptides | 1 day ago | Final Review | Refined |
Clinical Reports
Outcome metrics, biomarker trends, protocol performance
Avg Outcome Score
Last 6 months
91%
↑ 4pts
Protocol Adherence
Active patients
94%
↑ 6pts
Blueprints Generated
This quarter
18
↑ 8 vs Q1
Avg Time to Blueprint
From intake
36h
↓ 12h faster
🏆 Top Performing Protocols — Meridian Wellness
| Protocol | Patients | Avg Outcome | Key Peptide | Variant Target | Status |
|---|---|---|---|---|---|
| IL6 Inflammatory — MTHFR Modified | 6 | 94% | BPC-157 + TB-500 | IL6 / MTHFR | Active |
| Methylation Optimization | 4 | 91% | BPC-157 + Epitalon | MTHFR C677T | Active |
| Cellular Recovery — Exosome | 3 | 88% | Epitalon + Thymosin | TGF-β / IGF-1 | Monitoring |
| Stress Adaptation — HPA Axis | 2 | 82% | Selank + Semax | COMT Val158Met | Monitoring |